Key facts
- Ribbon Bio’s last known valuation is $46.6M (Feb 2025).
- It has raised $27.3M; the latest was Later Stage VC ($5.2M) in Feb 2025.
- Notable investors include Austria Wirtschaftsservice, Lansdowne Partners, EIC Scaling Club, Hadean Ventures, Helicase Venture — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Ribbon Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Ribbon Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Ribbon Bio
Developer of DNA technologies designed to meet the tailored needs of synthetic biology. The company's services offer deoxyribonucleic acid for the upcoming wave of biotechnologies whether it is required to build genomes, build high-throughput libraries, make new products based on deoxyribonucleic acid, store data, compute with deoxyribonucleic acid or build deoxyribonucleic acid-based nanotechnologies devices, enabling researchers and companies to focus on libraries of deoxyribonucleic acids of lengths base pairs without economic or time constraints.
- Sector
- Healthcare
- HQ
- Vienna, Austria
- Founded
- 2017
- Employees
- 54
- Website
- ribbonbio.com/
- Ownership
- Privately Held (backing)
Ribbon Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Ribbon Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Ribbon Bio in its N-PORT filings yet. We sweep new filings monthly.